AUTHOR=Mateos-Chávez Armando Alfredo , Muñoz-López Paola , Becerra-Báez Elayne Irene , Flores-Martínez Luis Fernando , Prada-Gracia Diego , Moreno-Vargas Liliana Marisol , Baay-Guzmán Guillermina Juliana , Juárez-Hernández Uriel , Chávez-Munguía Bibiana , Cabrera-Muñóz Lourdes , Luria-Pérez Rosendo TITLE=Live Attenuated Salmonella enterica Expressing and Releasing Cell-Permeable Bax BH3 Peptide Through the MisL Autotransporter System Elicits Antitumor Activity in a Murine Xenograft Model of Human B Non-hodgkin's Lymphoma JOURNAL=Frontiers in Immunology VOLUME=10 YEAR=2019 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02562 DOI=10.3389/fimmu.2019.02562 ISSN=1664-3224 ABSTRACT=
The survival of patients with non-Hodgkin's lymphoma (NHL) has substantially improved with current treatments. Nevertheless, the appearance of drug-resistant cancer cells leads to patient relapse. It is therefore necessary to find new antitumor therapies that can completely eradicate transformed cells. Chemotherapy-resistant cancer cells are characterized by the overexpression of members of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein family, such as Bcl-XL, Bcl-2, and Mcl-1. We have recently shown that peptides derived from the BH3 domain of the pro-apoptotic Bax protein may antagonize the anti-apoptotic activity of the Bcl-2 family proteins, restore apoptosis, and induce chemosensitization of tumor cells. In this study, we investigated the feasibility of releasing this peptide into the tumor microenvironment using live attenuated